KAS
CGON icon

Kemnay Advisory Services’s CG Oncology CGON Stock Holding History

Kemnay Advisory Services’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.5K Buy
584
+439
+303% +$24.9K 0.01% 343
2025
Q4 		$6.02K Buy
+145
New +$6K ﹤0.01% 827

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kemnay Advisory Services's CGON Position: Q1 2026 in Review

Kemnay Advisory Services increased its CG Oncology (CGON) stake by 303% in Q1 2026, buying an estimated $24.9K and bringing the position to 584 shares worth $39.5K. The position accounts for 0.01% of the portfolio, ranked #343.

Kemnay Advisory Services first reported a position in CGON in Q4 2025 and has held it in 2 quarters since. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Kemnay Advisory Services held 584 shares of CG Oncology worth $39.5K as of Q1 2026.
  • Kemnay Advisory Services bought 439 CG Oncology shares in Q1 2026, an estimated $24.9K.
  • CG Oncology made up 0.01% of Kemnay Advisory Services's portfolio in Q1 2026, its #343 holding.
  • Kemnay Advisory Services first reported a position in CG Oncology in Q4 2025 and has held it in 2 quarters since.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Kemnay Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.